Skip to main content Skip to section navigation Skip to footer
News & Media Careers Contact
Carrick Therapeutics, Inc.
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors & Observers
    • Collaborators & Advisors
  • Science
    • Overview
    • CDK7 Biology Schematic
    • CDK12/13 Biology Schematic
    • Posters & Publications
  • Pipeline
    • Overview
    • CDK7 Inhibitor
    • CDK12/13 Inhibitor
  • Partnering
  • News & Media
  • Careers
  • Contact

Press Releases

News & Media

News & Media

  • Overview
  • Press Releases
  • IR Calendar
  • In The News
  • Posters & Publications
May 15, 2025 7:00am EDT

Carrick Therapeutics Announces New Clinical Data Supporting Biomarker-driven Patient Selection for Samuraciclib (CDK7i) in Combination with SERDs in Hormone Receptor Positive Advanced Breast Cancer

Sep 23, 2024 8:00am EDT

Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)

Jun 05, 2024 8:00am EDT

Carrick Therapeutics Establishes New Headquarters in Boston, Massachusetts

Feb 14, 2024 8:00am EST

Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer

Dec 15, 2023 8:00am EST

Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer

Oct 18, 2023 9:00am EDT

Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer

Sep 07, 2023 8:00am EDT

Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13

Jul 06, 2023 9:00am EDT

Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination

Dec 19, 2022 9:48am EST

Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to Evaluate Samuraciclib and Elacestrant Combination

Dec 01, 2022 8:05am EST

Carrick Therapeutics Closes Series C Financing

  • Page 1
  • Page 2
  • Page 3
  • Next Pagearrow_forward
rss_feed News RSS
©2025 Carrick Therapeutics, Inc. All Rights Reserved.
Privacy Policy Cookie Policy Disclaimer Sitemap Visit us on Linkedin Manage Cookie Preferences